COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece
Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefo...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2023-08, Vol.12 (17), p.5460 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | 5460 |
| container_title | Journal of clinical medicine |
| container_volume | 12 |
| creator | Bakirtzis, Christos Konstantinidou, Natalia Stavropoulou De Lorenzo, Sotiria Moysiadis, Theodoros Boziki, Marina-Kleopatra Grigoriadou, Eleni Kesidou, Evangelia Theotokis, Paschalis Thireos, Eleftherios Mitrou, Panagiota Grigoriadis, Nikolaos |
| description | Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefore, data with regard to COVID-19 disease outcomes in these populations may provide additional insight with regard to the management of chronic diseases during viral pandemics. The objective of this study is to evaluate COVID-19 disease course in people with multiple sclerosis (PwMS) during the COVID-19 pandemic in Greece and explore the impact of vaccination in the outcome of SARS-CoV-2 infection in this population. Anonymized data, extracted from nationwide administrative records between February 2020 and December 2021, were retrospectively analyzed in order to identify PwMS with SARS-CoV-2 infection. Demographic data, as well as data regarding COVID-19 infection and vaccination, were additionally collected. The study sample included 2351 PwMS (65.1% females, 51.2% unvaccinated at the time of infection). A total of 260 PwMS were hospitalized, while 25 PwMS died from COVID-19 disease and its complications. Older age, male sex and the presence of comorbidities were independently associated with a higher probability of hospitalization. The risk of hospitalization was decreased in PwMS receiving some disease-modifying treatments. Anti-CD20s demonstrated high odds ratios without reaching statistical significance. Regarding fatal outcome, only age reached statistical significance. Vaccination provided a significant protective effect against hospitalization but did not exhibit a statistically significant effect on mortality. |
| doi_str_mv | 10.3390/jcm12175460 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10488265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A764266591</galeid><sourcerecordid>A764266591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-d522ab9ba838dbef2b4decb4ac952f8f572189010b267cbbed524fcf76b781863</originalsourceid><addsrcrecordid>eNptkl1L5TAQhoO4qLhe-QcK3ghSTdI0Sa9Ejp_g4oKrtyFJJ5pDmxybVvHfm6K4umxyMfl43neYYRDaJfiwqhp8tLQ9oUTUjOM1tEWxECWuZLX-5byJdlJa4rykZJndQJuV4LKuqdxCt4ub-6vTkjTFvbbWBz36GAod2uLUJ9AJikWchhx8KH5DXHVQvPjxsfg1daOfb7e2gyEmn2biYgCw8BP9cLpLsPMRt9Hd-dmfxWV5fXNxtTi5Li0jdCzbmlJtGqNlJVsDjhrWgjVM26amTrpaUCIbTLChXFhjIAuYs05wIySRvNpGx---q8n00FoI46A7tRp8r4dXFbVX33-Cf1QP8VkRzKSkvM4O-x8OQ3yaII2q98lC1-kAcUqK5iy0aQSek-39gy5zY0Kub6aoYBJL_Jd60B0oH1zMie1sqk4EZ5TzuiGZOvwPlXcLvbcxgPP5_Zvg4F1gc6vTAO6zSILVPAfqyxxUb2fUoZk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2862748080</pqid></control><display><type>article</type><title>COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bakirtzis, Christos ; Konstantinidou, Natalia ; Stavropoulou De Lorenzo, Sotiria ; Moysiadis, Theodoros ; Boziki, Marina-Kleopatra ; Grigoriadou, Eleni ; Kesidou, Evangelia ; Theotokis, Paschalis ; Thireos, Eleftherios ; Mitrou, Panagiota ; Grigoriadis, Nikolaos</creator><creatorcontrib>Bakirtzis, Christos ; Konstantinidou, Natalia ; Stavropoulou De Lorenzo, Sotiria ; Moysiadis, Theodoros ; Boziki, Marina-Kleopatra ; Grigoriadou, Eleni ; Kesidou, Evangelia ; Theotokis, Paschalis ; Thireos, Eleftherios ; Mitrou, Panagiota ; Grigoriadis, Nikolaos</creatorcontrib><description>Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefore, data with regard to COVID-19 disease outcomes in these populations may provide additional insight with regard to the management of chronic diseases during viral pandemics. The objective of this study is to evaluate COVID-19 disease course in people with multiple sclerosis (PwMS) during the COVID-19 pandemic in Greece and explore the impact of vaccination in the outcome of SARS-CoV-2 infection in this population. Anonymized data, extracted from nationwide administrative records between February 2020 and December 2021, were retrospectively analyzed in order to identify PwMS with SARS-CoV-2 infection. Demographic data, as well as data regarding COVID-19 infection and vaccination, were additionally collected. The study sample included 2351 PwMS (65.1% females, 51.2% unvaccinated at the time of infection). A total of 260 PwMS were hospitalized, while 25 PwMS died from COVID-19 disease and its complications. Older age, male sex and the presence of comorbidities were independently associated with a higher probability of hospitalization. The risk of hospitalization was decreased in PwMS receiving some disease-modifying treatments. Anti-CD20s demonstrated high odds ratios without reaching statistical significance. Regarding fatal outcome, only age reached statistical significance. Vaccination provided a significant protective effect against hospitalization but did not exhibit a statistically significant effect on mortality.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm12175460</identifier><identifier>PMID: 37685528</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Care and treatment ; Chronic illnesses ; Clinical medicine ; Coronavirus infections ; COVID-19 vaccines ; Development and progression ; Diabetes ; Disease ; Ethics ; Hospitalization ; Hypotheses ; Hypothesis testing ; Infections ; Multiple sclerosis ; Pandemics ; Patient outcomes ; Population ; Regression analysis ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Viral infections</subject><ispartof>Journal of clinical medicine, 2023-08, Vol.12 (17), p.5460</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-d522ab9ba838dbef2b4decb4ac952f8f572189010b267cbbed524fcf76b781863</cites><orcidid>0000-0002-6601-5163 ; 0000-0002-4737-3707 ; 0000-0003-1673-196X ; 0000-0001-8607-6695 ; 0000-0002-4278-3301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488265/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488265/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids></links><search><creatorcontrib>Bakirtzis, Christos</creatorcontrib><creatorcontrib>Konstantinidou, Natalia</creatorcontrib><creatorcontrib>Stavropoulou De Lorenzo, Sotiria</creatorcontrib><creatorcontrib>Moysiadis, Theodoros</creatorcontrib><creatorcontrib>Boziki, Marina-Kleopatra</creatorcontrib><creatorcontrib>Grigoriadou, Eleni</creatorcontrib><creatorcontrib>Kesidou, Evangelia</creatorcontrib><creatorcontrib>Theotokis, Paschalis</creatorcontrib><creatorcontrib>Thireos, Eleftherios</creatorcontrib><creatorcontrib>Mitrou, Panagiota</creatorcontrib><creatorcontrib>Grigoriadis, Nikolaos</creatorcontrib><title>COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece</title><title>Journal of clinical medicine</title><description>Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefore, data with regard to COVID-19 disease outcomes in these populations may provide additional insight with regard to the management of chronic diseases during viral pandemics. The objective of this study is to evaluate COVID-19 disease course in people with multiple sclerosis (PwMS) during the COVID-19 pandemic in Greece and explore the impact of vaccination in the outcome of SARS-CoV-2 infection in this population. Anonymized data, extracted from nationwide administrative records between February 2020 and December 2021, were retrospectively analyzed in order to identify PwMS with SARS-CoV-2 infection. Demographic data, as well as data regarding COVID-19 infection and vaccination, were additionally collected. The study sample included 2351 PwMS (65.1% females, 51.2% unvaccinated at the time of infection). A total of 260 PwMS were hospitalized, while 25 PwMS died from COVID-19 disease and its complications. Older age, male sex and the presence of comorbidities were independently associated with a higher probability of hospitalization. The risk of hospitalization was decreased in PwMS receiving some disease-modifying treatments. Anti-CD20s demonstrated high odds ratios without reaching statistical significance. Regarding fatal outcome, only age reached statistical significance. Vaccination provided a significant protective effect against hospitalization but did not exhibit a statistically significant effect on mortality.</description><subject>Care and treatment</subject><subject>Chronic illnesses</subject><subject>Clinical medicine</subject><subject>Coronavirus infections</subject><subject>COVID-19 vaccines</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Ethics</subject><subject>Hospitalization</subject><subject>Hypotheses</subject><subject>Hypothesis testing</subject><subject>Infections</subject><subject>Multiple sclerosis</subject><subject>Pandemics</subject><subject>Patient outcomes</subject><subject>Population</subject><subject>Regression analysis</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Viral infections</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkl1L5TAQhoO4qLhe-QcK3ghSTdI0Sa9Ejp_g4oKrtyFJJ5pDmxybVvHfm6K4umxyMfl43neYYRDaJfiwqhp8tLQ9oUTUjOM1tEWxECWuZLX-5byJdlJa4rykZJndQJuV4LKuqdxCt4ub-6vTkjTFvbbWBz36GAod2uLUJ9AJikWchhx8KH5DXHVQvPjxsfg1daOfb7e2gyEmn2biYgCw8BP9cLpLsPMRt9Hd-dmfxWV5fXNxtTi5Li0jdCzbmlJtGqNlJVsDjhrWgjVM26amTrpaUCIbTLChXFhjIAuYs05wIySRvNpGx---q8n00FoI46A7tRp8r4dXFbVX33-Cf1QP8VkRzKSkvM4O-x8OQ3yaII2q98lC1-kAcUqK5iy0aQSek-39gy5zY0Kub6aoYBJL_Jd60B0oH1zMie1sqk4EZ5TzuiGZOvwPlXcLvbcxgPP5_Zvg4F1gc6vTAO6zSILVPAfqyxxUb2fUoZk</recordid><startdate>20230823</startdate><enddate>20230823</enddate><creator>Bakirtzis, Christos</creator><creator>Konstantinidou, Natalia</creator><creator>Stavropoulou De Lorenzo, Sotiria</creator><creator>Moysiadis, Theodoros</creator><creator>Boziki, Marina-Kleopatra</creator><creator>Grigoriadou, Eleni</creator><creator>Kesidou, Evangelia</creator><creator>Theotokis, Paschalis</creator><creator>Thireos, Eleftherios</creator><creator>Mitrou, Panagiota</creator><creator>Grigoriadis, Nikolaos</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6601-5163</orcidid><orcidid>https://orcid.org/0000-0002-4737-3707</orcidid><orcidid>https://orcid.org/0000-0003-1673-196X</orcidid><orcidid>https://orcid.org/0000-0001-8607-6695</orcidid><orcidid>https://orcid.org/0000-0002-4278-3301</orcidid></search><sort><creationdate>20230823</creationdate><title>COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece</title><author>Bakirtzis, Christos ; Konstantinidou, Natalia ; Stavropoulou De Lorenzo, Sotiria ; Moysiadis, Theodoros ; Boziki, Marina-Kleopatra ; Grigoriadou, Eleni ; Kesidou, Evangelia ; Theotokis, Paschalis ; Thireos, Eleftherios ; Mitrou, Panagiota ; Grigoriadis, Nikolaos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-d522ab9ba838dbef2b4decb4ac952f8f572189010b267cbbed524fcf76b781863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Care and treatment</topic><topic>Chronic illnesses</topic><topic>Clinical medicine</topic><topic>Coronavirus infections</topic><topic>COVID-19 vaccines</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Ethics</topic><topic>Hospitalization</topic><topic>Hypotheses</topic><topic>Hypothesis testing</topic><topic>Infections</topic><topic>Multiple sclerosis</topic><topic>Pandemics</topic><topic>Patient outcomes</topic><topic>Population</topic><topic>Regression analysis</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakirtzis, Christos</creatorcontrib><creatorcontrib>Konstantinidou, Natalia</creatorcontrib><creatorcontrib>Stavropoulou De Lorenzo, Sotiria</creatorcontrib><creatorcontrib>Moysiadis, Theodoros</creatorcontrib><creatorcontrib>Boziki, Marina-Kleopatra</creatorcontrib><creatorcontrib>Grigoriadou, Eleni</creatorcontrib><creatorcontrib>Kesidou, Evangelia</creatorcontrib><creatorcontrib>Theotokis, Paschalis</creatorcontrib><creatorcontrib>Thireos, Eleftherios</creatorcontrib><creatorcontrib>Mitrou, Panagiota</creatorcontrib><creatorcontrib>Grigoriadis, Nikolaos</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakirtzis, Christos</au><au>Konstantinidou, Natalia</au><au>Stavropoulou De Lorenzo, Sotiria</au><au>Moysiadis, Theodoros</au><au>Boziki, Marina-Kleopatra</au><au>Grigoriadou, Eleni</au><au>Kesidou, Evangelia</au><au>Theotokis, Paschalis</au><au>Thireos, Eleftherios</au><au>Mitrou, Panagiota</au><au>Grigoriadis, Nikolaos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece</atitle><jtitle>Journal of clinical medicine</jtitle><date>2023-08-23</date><risdate>2023</risdate><volume>12</volume><issue>17</issue><spage>5460</spage><pages>5460-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefore, data with regard to COVID-19 disease outcomes in these populations may provide additional insight with regard to the management of chronic diseases during viral pandemics. The objective of this study is to evaluate COVID-19 disease course in people with multiple sclerosis (PwMS) during the COVID-19 pandemic in Greece and explore the impact of vaccination in the outcome of SARS-CoV-2 infection in this population. Anonymized data, extracted from nationwide administrative records between February 2020 and December 2021, were retrospectively analyzed in order to identify PwMS with SARS-CoV-2 infection. Demographic data, as well as data regarding COVID-19 infection and vaccination, were additionally collected. The study sample included 2351 PwMS (65.1% females, 51.2% unvaccinated at the time of infection). A total of 260 PwMS were hospitalized, while 25 PwMS died from COVID-19 disease and its complications. Older age, male sex and the presence of comorbidities were independently associated with a higher probability of hospitalization. The risk of hospitalization was decreased in PwMS receiving some disease-modifying treatments. Anti-CD20s demonstrated high odds ratios without reaching statistical significance. Regarding fatal outcome, only age reached statistical significance. Vaccination provided a significant protective effect against hospitalization but did not exhibit a statistically significant effect on mortality.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37685528</pmid><doi>10.3390/jcm12175460</doi><orcidid>https://orcid.org/0000-0002-6601-5163</orcidid><orcidid>https://orcid.org/0000-0002-4737-3707</orcidid><orcidid>https://orcid.org/0000-0003-1673-196X</orcidid><orcidid>https://orcid.org/0000-0001-8607-6695</orcidid><orcidid>https://orcid.org/0000-0002-4278-3301</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2023-08, Vol.12 (17), p.5460 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10488265 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Care and treatment Chronic illnesses Clinical medicine Coronavirus infections COVID-19 vaccines Development and progression Diabetes Disease Ethics Hospitalization Hypotheses Hypothesis testing Infections Multiple sclerosis Pandemics Patient outcomes Population Regression analysis Severe acute respiratory syndrome coronavirus 2 Statistical analysis Viral infections |
| title | COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T05%3A37%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20Vaccination%20and%20Disease%20Course%20in%20People%20with%20Multiple%20Sclerosis%20in%20Greece&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Bakirtzis,%20Christos&rft.date=2023-08-23&rft.volume=12&rft.issue=17&rft.spage=5460&rft.pages=5460-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm12175460&rft_dat=%3Cgale_pubme%3EA764266591%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2862748080&rft_id=info:pmid/37685528&rft_galeid=A764266591&rfr_iscdi=true |